Welcome to our dedicated page for Ifabric news (Ticker: IFABF), a resource for investors and traders seeking the latest updates and insights on Ifabric stock.
iFabric Corp. reports developments in technology-enhanced apparel and intelligent fabrics through its wholly owned subsidiary Intelligent Fabric Technologies (North America) Inc. Company updates frequently cover medical apparel programs such as Doctor's Choice scrubs and Frontline scrubs, along with proprietary textile technologies including PROTX2 antimicrobial treatment, ecoPEL fluorine-free durable water repellent technology, and DryTX moisture management.
Recurring news also includes financial results, revenue outlooks, retailer program expansions, and new product categories that apply IFTNA technologies to performance apparel, footwear, bedding, and other finished goods. The company's public updates also reference brand and retail programs including Verzus All Apparel, Roots branded footwear, and the Coconut Grove subsidiary within iFabric's broader operating structure.
iFabric (OTCQX:IFABF) announced that its subsidiary Intelligent Fabric Technologies (North America) Inc. has begun the launch of Doctor's Choice Next Generation scrubs with an initial rollout at a leading U.S. national big-box retailer. The first collections integrate IFTNA flagship technologies: PROTX2 (advanced antimicrobial), ecoPEL (C0 PFC-free DWR), and DryTX (moisture management).
Collections will launch online first, with in-store availability expected at the end of October 2025. Product claims include clinically proven antimicrobial finish, PFC-free water repellency, and wicking/quick-dry performance designed for clinical use.
iFabric Corp (OTCQX:IFABF) has announced that its subsidiary, Intelligent Fabric Technologies North America (IFTNA), has signed a significant licensing agreement with Mercury Athletics LLC to develop next-generation medical apparel under the Doctor's Choice® brand.
The collaboration will incorporate IFTNA's textile technologies, particularly PROTX2®, into healthcare scrubs and apparel. The partnership builds on Doctor's Choice's established reputation in diabetic and compression socks, expanding into the healthcare apparel sector. The new product line will be supported by IFTNA's peer-reviewed clinical trial published in the Journal of Hospital Infection in 2025.
iFabric Corp (OTCQX:IFABF) has renewed its license agreement with TUMI through its subsidiary Intelligent Fabric Technologies North America (IFTNA). The five-year extension continues the integration of IFTNA's PROTX2® antimicrobial technology across select TUMI products.
The renewed partnership will maintain PROTX2 implementation in TUMI's premium product lines, including the 19 Degree Polycarbonate carry-on linings, Travel Kits, Toiletry Kits, Laundry Bags, and select items within the Alpha Bravo, Alpha, Arrive' and McLaren collections.
iFabric Corp (OTCQX:IFABF) announced the expansion of its PROTX2 technology into the United Kingdom and European Union markets, marking a significant strategic expansion beyond North America. The company has secured a notable partnership with Marks & Spencer, which will incorporate PROTX2 technology into select items within its Autograph collections.
The PROTX2 brand mark will be prominently featured on merchandise hang tags both in-store and online, increasing brand visibility in these new regional markets. The company's Intelligent Fabric Technologies Division will support production programs incorporating PROTX2 technology in both the EU and UK regions.
iFabric Corp (OTCQX:IFABF) has announced the publication of groundbreaking clinical trial results in the Journal of Hospital Infection, demonstrating the effectiveness of their PROTX2® and ecoPEL™ antimicrobial technologies in healthcare settings.
The trial, conducted at MemorialCare Saddleback Medical Center, is the first successful antimicrobial textile trial to show statistically significant bacterial load reductions on scrubs in a real-world healthcare environment. The study validates that scrubs treated with PROTX2® and PROTX2® combined with ecoPEL™ significantly reduce surface bacterial contamination compared to untreated scrubs.
PROTX2® is EPA-registered and available for use throughout the United States, positioning IFTNA as a leader in healthcare-associated infection prevention solutions.
iFabric Corp (OTCQX:IFABF) reported its Q2 and H1 2025 financial results, with Q2 revenues remaining flat at $5.8 million compared to 2024. The company's H1 2025 revenues increased by 5% to $12.9 million. Q2 gross profit margin decreased to 37% from 42% in 2024, primarily due to $350,000 in brand advertising contributions.
The Intimate Apparel Division showed growth with a 10% revenue increase, while the Intelligent Fabrics Division saw a 7% decrease. The company reported a Q2 2025 net loss of $190,103 ($0.006 per share) compared to net earnings of $56,103 in 2024. Working capital remained strong at $19.2 million, with an unused $12 million credit facility available for future growth.
iFabric (OTCQX:IFABF) held its 2025 Annual General Meeting with approximately 65% shareholder participation, representing 19.5 million shares. All proposed matters received majority approval. The election of directors saw overwhelming support, with all six nominees receiving over 98.85% approval.
Shareholders also approved the appointment of BDO Canada LLP as auditors and fixed the number of directors at six. Notable directors Hylton Karon and Richard Macary received 99.86% and 99.94% of votes in favor, respectively.
iFabric Corp (IFABF) reported record Q1 2025 revenues of $7.08 million, a 5% increase from Q1 2024. The Intelligent Fabrics Division saw a 25% revenue increase to $5.82 million, while the Intimate Apparel Division experienced a 40% decrease to $1.25 million. Gross profit margins declined to 39% from 44%, resulting in a net earnings decrease to $88,458 ($0.003 per share) from $550,596 ($0.018 per share) in Q1 2024.
The company faces increased U.S. tariffs on Chinese imports (30%, up 10%), affecting 23% of total revenue. Cash position strengthened to $5.64 million, and the company expanded its bank operating line to $12 million. Management anticipates continued momentum and new product segments launch later in 2025, despite regulatory costs and ongoing leaching study expenses for Protx2.
iFabric Corp (IFABF) has announced two significant financial developments: First, the acquisition of the remaining 25% stake in its Markham, Ontario warehouse property subsidiary through a CDN$3.7 million mortgage financing from BMO. This financing will also be used to repay existing secured and minority shareholder loans.
Second, the company has secured a new banking agreement with BMO that increases its revolving operating credit facility from $6.75 million to $12 million. The facility, currently unutilized, is secured by company assets including a mortgage on the Markham property, which was recently valued at approximately $12 million.